Islatravir Is Not Expected to Be a Victim or Perpetrator of Drug-Drug Interactions via Major Drug-Metabolizing Enzymes or Transporters
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Islatravir Is Not Expected to Be a Victim or Perpetrator of Drug-Drug Interactions via Major Drug-Metabolizing Enzymes or Transporters
Authors
Keywords
-
Journal
Viruses-Basel
Volume 13, Issue 8, Pages 1566
Publisher
MDPI AG
Online
2021-08-09
DOI
10.3390/v13081566
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Phase 1 Study to Evaluate the Drug Interaction Between Islatravir (MK-8591) and Doravirine in Adults Without HIV
- (2021) Randolph P. Matthews et al. CLINICAL DRUG INVESTIGATION
- The challenge of HIV treatment in an era of polypharmacy
- (2020) David Back et al. Journal of the International AIDS Society
- Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial
- (2020) Dirk Schürmann et al. Lancet HIV
- Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine
- (2020) Sabrina T. Wiebe et al. CLINICAL PHARMACOKINETICS
- Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults With and Without HIV Infection, 2000-2016
- (2020) Julia L. Marcus et al. JAMA Network Open
- High-dose naloxone, an experimental tool uncovering latent sensitisation: pharmacokinetics in humans
- (2019) Theodoros Papathanasiou et al. BRITISH JOURNAL OF ANAESTHESIA
- Clinical Studies on Drug‐Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls and Interpretation
- (2019) Aleksi Tornio et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- In Vitro Evaluation of the Drug Interaction Potential of Doravirine
- (2019) Kelly Bleasby et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Comorbidities in Persons With HIV
- (2019) Andrea M. Lerner et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Islatravir for the treatment and prevention of infection with the human immunodeficiency virus type 1
- (2019) Martin Markowitz et al. Current Opinion in HIV and AIDS
- Understanding mechanisms to promote successful aging in persons living with HIV
- (2018) Gerome V. Escota et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans
- (2018) Rosa I. Sanchez et al. XENOBIOTICA
- 4′-Ethynyl-2-fluoro-2′-deoxyadenosine, MK-8591
- (2018) Martin Markowitz et al. Current Opinion in HIV and AIDS
- Can BSEP Inhibition Testing In Drug Discovery And Development Reduce Liver Injury Risk? - An International Transporter Consortium Perspective
- (2018) J Gerry Kenna et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Comorbidities Among US Patients With Prevalent HIV Infection—A Trend Analysis
- (2017) Joel Gallant et al. JOURNAL OF INFECTIOUS DISEASES
- Chronic health conditions in Medicare beneficiaries 65 years and older with HIV infection
- (2016) Eleanor E. Friedman et al. AIDS
- Renal Transporter-Mediated Drug-Drug Interactions: Are They Clinically Relevant?
- (2016) Eve-Irene Lepist et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Structural basis of HIV inhibition by translocation-defective RT inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA)
- (2016) Zhe Li Salie et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Clinically and pharmacologically relevant interactions of antidiabetic drugs
- (2016) Marcus May et al. Therapeutic Advances in Endocrinology and Metabolism
- Oral Administration of the Nucleoside EFdA (4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine) Provides Rapid Suppression of HIV Viremia in Humanized Mice and Favorable Pharmacokinetic Properties in Mice and the Rhesus Macaque
- (2015) Cheryl A. Stoddart et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel
- (2015) Xi-Ling Jiang et al. CLINICAL PHARMACOKINETICS
- Future challenges for clinical care of an ageing population infected with HIV: a modelling study
- (2015) Mikaela Smit et al. LANCET INFECTIOUS DISEASES
- Comparison of VerifyNow P2Y12 and thrombelastography for assessing clopidogrel response in stroke patients in China
- (2015) Hui-Hui Lv et al. NEUROLOGICAL SCIENCES
- Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update
- (2014) Qingcheng Mao et al. AAPS Journal
- 4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) Inhibits HIV-1 Reverse Transcriptase with Multiple Mechanisms
- (2014) Eleftherios Michailidis et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A clinician's guide to statin drug-drug interactions
- (2014) Kenneth A. Kellick et al. Journal of Clinical Lipidology
- Polypharmacy, Drug-Drug Interactions, and Potentially Inappropriate Medications in Older Adults with Human Immunodeficiency Virus Infection
- (2014) Meredith Greene et al. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
- Cause-Specific Life Expectancies After 35 Years of Age for Human Immunodeficiency Syndrome-Infected and Human Immunodeficiency Syndrome-Negative Individuals Followed Simultaneously in Long-term Cohort Studies, 1984–2008
- (2013) Nikolas Wada et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- Role of Hepatic Efflux Transporters in Regulating Systemic and Hepatocyte Exposure to Xenobiotics
- (2013) Nathan D. Pfeifer et al. Annual Review of Pharmacology and Toxicology
- Effects of Substitutions at the 4′ and 2 Positions on the Bioactivity of 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine
- (2013) Karen A. Kirby et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Raltegravir Has a Low Propensity To Cause Clinical Drug Interactions through Inhibition of Major Drug Transporters: anIn VitroEvaluation
- (2013) Matthew L. Rizk et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
- (2013) Ulrich M. Zanger et al. PHARMACOLOGY & THERAPEUTICS
- Understanding the Critical Disposition Pathways of Statins to Assess Drug–Drug Interaction Risk During Drug Development: It's Not Just About OATP1B1
- (2012) R Elsby et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Premature Age-Related Comorbidities Among HIV-Infected Persons Compared With the General Population
- (2011) G. Guaraldi et al. CLINICAL INFECTIOUS DISEASES
- Clinical Pharmacokinetics of Metformin
- (2011) Garry G. Graham et al. CLINICAL PHARMACOKINETICS
- Impact of proton pump inhibitors on efficacy of clopidogrel: Review of evidence
- (2011) PrashantS Dalvi et al. INDIAN JOURNAL OF PHARMACOLOGY
- Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate
- (2010) Laurent Bonello et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Very important pharmacogene summary
- (2010) Laura M. Hodges et al. Pharmacogenetics and Genomics
- ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin
- (2009) J E Keskitalo et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Effect of Rifampin and Nelfinavir on the Metabolism of Methadone and Buprenorphine in Primary Cultures of Human Hepatocytes
- (2009) D. E. Moody et al. DRUG METABOLISM AND DISPOSITION
- Mechanism of Inhibition of HIV-1 Reverse Transcriptase by 4′-Ethynyl-2-fluoro-2′-deoxyadenosine Triphosphate, a Translocation-defective Reverse Transcriptase Inhibitor
- (2009) Eleftherios Michailidis et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Substrates and Inhibitors of Human Multidrug Resistance Associated Proteins and the Implications in Drug Development
- (2008) Shu-Feng Zhou et al. CURRENT MEDICINAL CHEMISTRY
- 2′-Deoxy-4′-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants
- (2008) Atsushi Kawamoto et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search